Jul 20, 2026 07:00AM
Jul 20, 2026 07:00AM
Jun 26, 2026 07:01AM
Jun 26, 2026 07:00AM
May 18, 2026 07:01AM
May 18, 2026 07:00AM
May 13, 2026 07:00AM Can-Fite advances pancreatic cancer drug to phase 2b trial
May 13, 2026 07:00AM
Apr 30, 2026 08:31AM
Apr 30, 2026 08:31AM
Mar 26, 2026 09:28AM
Mar 26, 2026 09:27AM
Mar 17, 2026 07:47AM
Mar 4, 2026 10:26AM Can-Fite raises $4 million through warrant exercise agreement
Mar 4, 2026 10:25AM
Dec 23, 2025 04:46PM
Dec 16, 2025 09:19AM
Nov 26, 2025 07:00AM
Jul 30, 2025 07:04AM
Jul 30, 2025 07:04AM
Jul 28, 2025 12:24PM Can-Fite prices $15 million public offering with institutional investor
Jul 28, 2025 12:24PM
Apr 14, 2025 02:29PM
Apr 14, 2025 02:28PM
Apr 14, 2025 08:00AM
Mar 24, 2025 09:00AM
Feb 18, 2025 07:00AM
Feb 10, 2025 07:10AM Join Can-Fite’s Exclusive Live Investor Webinar and Q&A Session on February 25
Feb 5, 2025 07:00AM
Jan 27, 2025 07:00AM
Nov 4, 2024 07:08AM
Oct 18, 2024 09:11AM
Oct 18, 2024 09:06AM
Oct 7, 2024 07:00AM
Sep 16, 2024 07:00AM Can-Fite: Pancreatic Carcinoma Phase IIa Clinical Study with Namodenoson Received Regulatory Authorization from the Israeli Ministry of Health
Aug 29, 2024 08:15AM
Jul 17, 2024 07:00AM
Nov 21, 2023 01:53PM
Mar 13, 2023 07:00AM
Dec 28, 2022 07:01AM
Dec 28, 2022 07:00AM
Dec 8, 2022 07:00AM Can-Fite’s Partner Vetbiolix is Heading into a European Multicentric Clinical Trial with Piclidenoson for the Treatment of Pets’ Osteoarthritis
Nov 25, 2022 07:00AM
Nov 2, 2022 07:15AM
Oct 25, 2022 07:00AM
Oct 13, 2022 07:00AM
Sep 12, 2022 07:00AM
Aug 25, 2022 07:00AM
Aug 23, 2022 07:00AM Can-Fite’s Drug Namodenoson Approved for Compassionate Use Treatment of Advanced Liver Cancer Patients in Romania
Aug 22, 2022 07:00AM

326,554 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All